Global Plasma Fractionation Market Insights Forecasts to 2032
- The Global Plasma Fractionation Market Size was valued at USD 27.1 Billion in 2022.
- The Market Size is Growing at a CAGR of 6.7% from 2022 to 2032
- The Worldwide Plasma Fractionation Market Size is expected to reach USD 51.8 Billion by 2032
- Asia Pacific is expected to Grow the fastest during the forecast period
Get more details on this report -
The Global Plasma Fractionation Market size is anticipated to exceed USD 51.8 Billion by 2032, Growing at a CAGR of 6.7% from 2022 to 2032. The growing prevalence of elderly people around the world, who are more susceptible to rare disorders that necessitate the use of blood derivatives, is a major driver of the market's expansion. Furthermore, the increased use of immunoglobulins and alpha-1-antitrypsin in various fields of medicine worldwide is expected to drive market growth. Another important factor driving the growth of this market is the increase in blood collection facilities around the world.
The global plasma fractionation market refers to the rapidly growing healthcare industry dedicated to the separation and purification of blood plasma components for therapeutic and diagnostic purposes. The liquid portion of blood, blood plasma, contains vital proteins and antibodies that are required for various medical treatments. Plasma fractionation is the process of isolating and concentrating these valuable components so that they can be used to treat a variety of medical conditions. It provides essential medical products such as immunoglobulins, clotting factors, albumin, and serum albumin, which are critical in the treatment of patients suffering from autoimmune disorders, bleeding disorders, immune deficiencies, and other conditions. These therapies improve patients' quality of life and, in some cases, can save their lives. The global plasma fractionation market has witnessed significant growth in recent years due to increasing demand for plasma-derived therapies, advancements in fractionation technology, and a growing awareness of these treatments. This market encompasses a wide range of stakeholders, including plasma collection centers, manufacturers, healthcare providers, and patients. As the prevalence of chronic diseases continues to rise worldwide, the global plasma fractionation market is poised for sustained expansion, offering hope and improved healthcare outcomes for countless individuals.
This research report categorizes the market for the global plasma fractionation market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the plasma fractionation market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the plasma fractionation market.
Global Plasma Fractionation Market Report Coverage
|Market Size in 2022:||USD 27.1 Billion|
|Forecast Period 2022-2032 CAGR:||6.7%|
|2032 Value Projection:||USD 51.8 Billion|
|Historical Data for:||2018-2021|
|No. of Pages:||200|
|Tables, Charts & Figures:||130|
|Segments covered:||By Product, By Application, By End User, By Region|
|Companies Covered:||CSL, Takeda Pharmaceutical company limited, Grifols, S.A., Octapharma AG, Kedrion S.P.A , LFB , ADMA Biologics, Sanquin, China Biologic Products Holdings Inc., GC Pharma, Hualan Bioengineering Co., Ltd., Japan Blood Products Organization, Emergent BioSolutions , Shanghai Raas Blood Products Co., Ltd., And other key venders|
|Pitfalls & Challenges:||COVID-19 Empact,Challenges, Future, Growth, & Analysis|
Get more details on this report -
The rising prevalence of chronic diseases such as immunodeficiency disorders, hemophilia, and liver disease has increased demand for plasma-derived therapies. Patients suffering from these diseases require regular access to clotting factors, immunoglobulins, and other plasma-derived products, fueling market growth. The world's aging population makes people more vulnerable to age-related diseases, including immune-related disorders. As the elderly population grows, so does the demand for plasma-based treatments, as these therapies are frequently required by the elderly to improve their quality of life. Governments and private organizations are investing heavily in healthcare infrastructure and research, making plasma therapies more accessible. This increased healthcare spending has created a favorable environment for the plasma fractionation market to expand.
The production of plasma-derived products is a time-consuming and expensive process that includes several steps such as plasma collection, fractionation, and purification. High production costs can make these therapies unaffordable, especially in emerging markets. Plasma, the primary raw material for fractionation, can be difficult to obtain. Plasma collection is heavily reliant on voluntary donations, and supply chain disruptions, such as during the COVID-19 pandemic, can result in shortages of plasma-derived products.
The Global Plasma Fractionation Market share is classified into product and application.
- The Immunoglobulins segment is expected to register significant growth rate in the global plasma fractionation market during the forecast period.
The global plasma fractionation market is categorized by product into Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, and PCC. Among these, the Immunoglobulins segment is expected to register significant growth rate in the global plasma fractionation market during the forecast period. Immunoglobulins, also known as antibodies, are proteins that play a vital role in the immune system's defense against infections. They are used to treat various immune deficiency disorders, autoimmune diseases, and neurological disorders. Immunoglobulins have historically held a significant share of the plasma fractionation market due to their widespread therapeutic applications and growing demand.
- The neurology segment accounted for the largest share of the global plasma fractionation market in 2022.
Based on the application, the global plasma fractionation market is divided into Neurology, Immunology, Hematology, and Rheumatology. Among these, the neurology segment accounted for the largest share of the global plasma fractionation market in 2022. In neurology, plasma-derived products like intravenous immunoglobulins (IVIG) are used to treat various neurological disorders, including Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), and myasthenia gravis. The neurology segment is significant due to the increasing prevalence of neurological disorders and the expanding applications of IVIG in this field.
Regional Segment Analysis of the Global Plasma Fractionation Market
- North America (U.S., Canada, Mexico)
- Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
- Asia-Pacific (China, Japan, India, Rest of APAC)
- South America (Brazil and the Rest of South America)
- The Middle East and Africa (UAE, South Africa, Rest of MEA)
North America is anticipated to hold a significant share of the global plasma fractionation market over the predicted timeframe.
Get more details on this report -
North America is projected to hold a significant share of the global plasma fractionation market over the predicted years. North America has long been one of the most important regions in the global plasma fractionation market. Because of its advanced healthcare infrastructure, high disease prevalence, and strong presence of major plasma product manufacturers, the United States, in particular, plays a pivotal role.
Asia Pacific is expected to grow at the fastest pace in the global plasma fractionation market during the forecast period. The Asia-Pacific region has grown greatly in recent years, owing to factors such as a large patient population, rising healthcare expenditure, and increased awareness of plasma-derived therapies. China and India are emerging as major players in this market.
The report offers the appropriate analysis of the key organizations/companies involved within the global plasma fractionation along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
List of Key Companies
- Takeda Pharmaceutical company limited
- Grifols, S.A.
- Octapharma AG
- Kedrion S.P.A
- ADMA Biologics
- China Biologic Products Holdings Inc.
- GC Pharma
- Hualan Bioengineering Co., Ltd.
- Japan Blood Products Organization
- Emergent BioSolutions
- Shanghai Raas Blood Products Co., Ltd.
Key Target Audience
- Market Players
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
- In April 2023, CSL (Australia) received FDA approval for the 50mL/10gm prefilled syringe for Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid) for patients with PI and CIPD.
This study forecasts revenue at global, regional, and country levels from 2020 to 2032. Spherical Insights has segmented the Global Plasma Fractionation Market based on the below-mentioned segments:
Global Plasma Fractionation Market, By Product
- Protease Inhibitors
- von Willebrand Factor
Global Plasma Fractionation Market, By Application
Global Plasma Fractionation Market, By End User
- Clinical Research
- Hospitals & Clinics
Global Plasma Fractionation Market, By Region
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- South America
- Rest of South America
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
Need help to buy this report?